 - UCLA Jonsson Comprehensive Cancer Center and Vanderbilt-Ingram Cancer Center will also participate - Study will evaluate the efficacy and safety of NERLYNX and FASLODEX in metastatic HR-positive, HER2-negative breast cancer patients selected by the CELsignia Test MINNEAPOLIS, MN ACCESSWIRE December 23, 2020 Celcuity Inc. NASDAQ:CELC, a clinical stage biotechnology company utilizing its 3rd generation companion diagnostics to identify new targeted therapeutic options for cancer patients, today announced a clinical trial collaboration with Massachusetts General Hospital and Puma Biotechnology, a biopharmaceutical company, to conduct a Phase II clinical trial. This open-label Phase II trial will evaluate the efficacy and safety of Pumas drug, NERLYNX neratinib, and FASLODEX fulvestrant, an AstraZeneca drug, in previously treated metastatic HR-positive HR, HER2-negative HER2- breast cancer patients selected with Celcuitys CELsignia HER2 Activity Test. 